Chordia Therapeutics Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Hiroshi Miyake
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 6.9yrs |
| CEO ownership | 1.4% |
| Management average tenure | no data |
| Board average tenure | 1.9yrs |
Recent management updates
No updates
Recent updates
CEO
Hiroshi Miyake (54 yo)
6.9yrs
Tenure
Mr. Hiroshi Miyake, Ph D., is Co-Founder of Chordia Therapeutics Inc. and serves as its President, Chief Executive Officer, and Representative Director since November 2017. He has experiences in drug disco...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 6.9yrs | no data | 1.36% ¥ 257.4m | |
| Independent External Director | 2yrs | no data | no data | |
| Independent External Director | 1.9yrs | no data | no data | |
| Independent External Director | 1.9yrs | no data | no data | |
| Independent External Director | 1.9yrs | no data | no data |
1.9yrs
Average Tenure
54yo
Average Age
Experienced Board: 190A's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.